The Relationships Between the Noradrenergic, Opioid and Pain System
Information source: Rambam Health Care Campus
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Experimental Pain Perception
Intervention: Clonidine (Drug); Naloxone (Drug); placebo (Drug); saline (Other)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Rambam Health Care Campus Overall contact:
David Yarnitsky, Prof., Email: d_yarnitsky@rambam.health.gov.il
Summary
The role of alpha2 receptor agonist on pain perception and modulation will be examined. In
addition whether this is mediated through the opioid system will be examined. Pain
perception and modulation will be examined before and after administration of Clonidine or
placebo together with Naloxone or saline.
Clinical Details
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Primary outcome: The changes in pain responses after administration of alpha 2 agonist and mu receptor antagonist
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy volunteers
- Age 18-40
- No chronic disease
Exclusion Criteria:
- Subjects who suffer from chronic pain / pain syndrome
- use of anti-depressant or anti-psychotic drugs
- suffering from cardiovascular disease
- breast feeding
Locations and Contacts
David Yarnitsky, Prof., Email: d_yarnitsky@rambam.health.gov.il
Rambam Health Care Campus, Haifa, Israel; Not yet recruiting
David Yarnitsky, Email: d_yarnitsky@rambam.health.gov.il
Additional Information
Starting date: May 2013
Last updated: May 9, 2013
|
